- Conditions
- Acquired Immune Deficiency Syndrome (AIDS), HIV Infections
- Interventions
- E/C/F/TAF, E/C/F/TAF (Low Dose)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2025
- U.S. locations
- 5
- States / cities
- Long Beach, California • Washington D.C., District of Columbia • Atlanta, Georgia + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 337–360
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
- Interventions
- Mesenchymal Stromal Cells, Supportive Care
- Biological · Other
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Castration-resistant Prostate Cancer, CRPC
- Interventions
- VT-464: given orally once daily in 28 day cycles
- Drug
- Lead sponsor
- Innocrin Pharmaceutical
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 5
- States / cities
- Tampa, Florida • Omaha, Nebraska • Durham, North Carolina + 2 more
- Conditions
- Breast Cancer
- Interventions
- Paclitaxel, Vinorelbine, Filgrastim, Radiation
- Drug · Radiation
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2012
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- ALL, Burkitt's Lymphoma, Lymphoblastic Leukemia, CML
- Interventions
- Rapamycin, High dose etoposide and cytarabine (HiVAC)
- Drug
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Asthma
- Interventions
- Fluticasone Propionate
- Drug
- Lead sponsor
- Dey
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 629 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 1
- States / cities
- Greenville, South Carolina
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Loncastuximab Tesirine and Acalabrutinib
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Sepsis
- Interventions
- personalized dosing adjustment of vancomycin
- Other
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Haemophilia A Without Inhibitors, Haemophilia B Without Inhibitors
- Interventions
- Concizumab
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 12 Years and older · Male only
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Orange, California • Augusta, Georgia + 9 more
- Conditions
- Knee Arthritis, Knee Osteoarthritis, Knee Pain Chronic, Knee Discomfort, Rheumatoid Arthritis, Knee Pain Swelling
- Interventions
- Gold Factor (Gold Nanoparticles, AuNPs), Placebo
- Dietary Supplement
- Lead sponsor
- 4Life Research, LLC
- Industry
- Eligibility
- 18 Years to 87 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Bacterial Infections
- Interventions
- Cefiderocol/Xeruborbactam
- Drug
- Lead sponsor
- Qpex Biopharma, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Miami, Florida • Orlando, Florida
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Idelalisib, Bendamustine, Rituximab, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 311 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Fullerton, California • La Jolla, California • Santa Maria, California + 20 more
- Conditions
- Platinum-resistant Ovarian Cancer
- Interventions
- Gemcitabine, N-803, M-CENK
- Drug · Biological
- Lead sponsor
- ImmunityBio, Inc.
- Industry
- Eligibility
- 18 Years to 85 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- El Segundo, California • Newport Beach, California
- Conditions
- Polyarticular-course Juvenile Idiopathic Arthritis (JIA)
- Interventions
- Certolizumab Pegol (CZP)
- Drug
- Lead sponsor
- UCB BIOSCIENCES GmbH
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 193 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2024
- U.S. locations
- 20
- States / cities
- Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Fibromyalgia
- Interventions
- Tramadol, Placebo, Cognitive Behavior Therapy for FM, Health Education
- Drug · Behavioral
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 134 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 2
- States / cities
- Rochester, New York • Seattle, Washington
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Cevostamab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Locally Advanced and Metastatic Solid Tumors
- Interventions
- Ociperlimab, Tislelizumab, Pemetrexed, Paclitaxel, Nab paclitaxel, Carboplatin, Cisplatin, Etoposide, 5fluorouracil, Oxaliplatin, Capecitabine
- Drug
- Lead sponsor
- BeiGene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 11
- States / cities
- Phoenix, Arizona • Fort Myers, Florida • Jacksonville, Florida + 8 more
- Conditions
- Carcinoma, Renal Cell, Kidney Neoplasms, Kidney Diseases
- Interventions
- AGS-16M18
- Biological
- Lead sponsor
- Astellas Pharma Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Extensive-stage Small Cell Lung Cancer
- Interventions
- Vorolanib, Atezolizumab
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Intraocular Melanoma, Melanoma (Skin)
- Interventions
- ipilimumab, Tyrosinase/gp100/MART-1 Peptides
- Biological
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 77 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Solid Tumor
- Interventions
- DS-1103a, T-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • New York, New York • Providence, Rhode Island + 2 more
- Conditions
- Lung Cancer, Head and Neck Cancer
- Interventions
- Panobinostat (LBH589), erlotinib
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2015
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Non-radiographic Spondyloarthritis
- Interventions
- Secukinumab, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 555 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Beverly Hills, California • Fullerton, California + 15 more
- Conditions
- Acute Myeloid Leukemia, Myeloid Neoplasm
- Interventions
- Liposome-encapsulated Daunorubicin-Cytarabine, Cladribine, Cytarabine, Recombinant Granulocyte Colony-Stimulating Factor, Mitoxantrone, Questionnaire Administration, Quality-of-Life Assessment
- Drug · Biological · Other
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Seattle, Washington